ANRO Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $9,700,614.00
Insider Selling (Last 12 Months): $0.00

Alto Neuroscience Insider Trading History Chart

This chart shows the insider buying and selling history at Alto Neuroscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alto Neuroscience Share Price & Price History

Current Price: $12.40
Price Change: Price Decrease of -0.07 (-0.56%)
As of 05/20/2024 01:00 AM ET

This chart shows the closing price history over time for ANRO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Alto Neuroscience Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2024Nicholas Conrad SmithCFOBuy6,150$16.36$100,614.0026,866View SEC Filing Icon  
2/6/2024Wave Global Lp AlphaMajor ShareholderBuy600,000$16.00$9,600,000.003,707,757View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Alto Neuroscience (NYSE:ANRO)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ANRO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alto Neuroscience Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2024RA Capital Management L.P.1,385,491$21.27M0.3%N/A5.154%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.350,000$5.37M0.1%N/A1.302%Search for SEC Filing on Google Icon
5/17/2024Zimmer Partners LP75,000$1.15M0.0%N/A0.279%Search for SEC Filing on Google Icon
5/16/2024AWM Investment Company Inc.299,147$4.59M0.6%N/A1.113%Search for SEC Filing on Google Icon
5/15/2024Price T Rowe Associates Inc. MD637,604$9.79M0.0%N/A2.372%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.536,332$8.23M0.0%N/A1.995%Search for SEC Filing on Google Icon
5/2/2024Jennison Associates LLC458,599$7.04M0.0%N/A1.706%Search for SEC Filing on Google Icon
4/30/2024University of Texas Texas AM Investment Managment Co.22,175$0.34M0.1%N/A0.082%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alto Neuroscience logo
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.
Read More on Alto Neuroscience

Today's Range

Now: $12.40
Low: $12.10
High: $12.77

50 Day Range

MA: $14.47
Low: $12.40
High: $17.90

52 Week Range

Now: $12.40
Low: $12.01
High: $24.00

Volume

97,284 shs

Average Volume

79,067 shs

Market Capitalization

$333.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alto Neuroscience?

Alto Neuroscience's top insider shareholders include:
  1. Wave Global Lp Alpha (Major Shareholder)
  2. Nicholas Conrad Smith (CFO)
Learn More about top insider investors at Alto Neuroscience.

Who are the major institutional investors of Alto Neuroscience?

Alto Neuroscience's top institutional investors include:
  1. RA Capital Management L.P. — 5.15%
  2. Price T Rowe Associates Inc. MD — 2.37%
  3. Vanguard Group Inc. — 1.99%
  4. Jennison Associates LLC — 1.71%
  5. Artal Group S.A. — 1.30%
  6. AWM Investment Company Inc. — 1.11%
Learn More about top institutional investors of Alto Neuroscience stock.

Which major investors are buying Alto Neuroscience stock?

During the previous quarter, ANRO stock was purchased by institutional investors including:
  1. RA Capital Management L.P.
  2. Price T Rowe Associates Inc. MD
  3. Vanguard Group Inc.
  4. Jennison Associates LLC
  5. Artal Group S.A.
  6. AWM Investment Company Inc.
  7. Zimmer Partners LP
  8. University of Texas Texas AM Investment Managment Co.
During the previous year, these company insiders have bought Alto Neuroscience stock:
  1. Wave Global Lp Alpha (Major Shareholder)
  2. Nicholas Conrad Smith (CFO)
Learn More investors buying Alto Neuroscience stock.